home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Sapphire Collection
/
Software Vault (Sapphire Collection) (Digital Impact).ISO
/
cdr14
/
med9410l.zip
/
M94A2017.TXT
< prev
next >
Wrap
Text File
|
1994-10-24
|
2KB
|
37 lines
Document 2017
DOCN M94A2017
TI Update on antiretroviral therapy.
DT 9412
AU Vella S; Instituto Superiore di Sanita, Rome, Italy.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):4 (abstract no. PS3). Unique
Identifier : AIDSLINE ICA10/94370558
AB The in vivo activity of the available anti-HIV compounds has been
clearly demonstrated by the results in the treatment of advanced HIV
disease and by the reduction of the vertical transmission rate. However,
it is also evident that the efficacy of monotherapy is of limited
duration, with drug-resistance probably playing a major role. With the
new insights into the pathogenesis of HIV-disease suggesting the need
for early intervention, and with the evidence that combination regimens
are more effective in reducing HIV viral load, the results of large
trials that clinically evaluate nucleoside combination regimens as
first-line treatments are eagerly waited. In perspective, protease
inhibitors which target a different virus enzyme and that have shown
promising results in phase II studies, may also represent a major
advance for combination regimens. In fact, the phenomenon of the
selection of drug-resistant strains may be reduced by further reducing
the HIV replication rate. Hopefully, the continuous progress in basic
science and in drug development will ultimately lead to the
identification of more efficient therapeutic strategies. However, a
global cooperative action to ensure the availability and the
accessibility of safe and effective drugs for developing countries
should be regarded as one of the future priorities.
DE Antiviral Agents/*ADMINISTRATION & DOSAGE/SUPPLY & DISTRIBUTION/
*THERAPEUTIC USE Developing Countries Drug Therapy, Combination Human
HIV/DRUG EFFECTS HIV Infections/*DRUG THERAPY/METABOLISM Protease
Inhibitors/THERAPEUTIC USE Virus Replication/DRUG EFFECTS MEETING
ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).